Brief Review of Survival in Brain Metastases: The Updated Diagnosis-Specific Graded Prognostic Assessment— Sperduto 2020
This is a brief audio review. In the article Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient published, 2020 by Sperduto and Colleagues, The outcomes and key points are as noted: The graded prognostic assessment tool for metastatic cancer to the brain has been updated due to median survival variability with patient cohort data accounting for new prognosis data, and molecular markers. Graded prognostic assessment score has been updated for improved prognoses and variation for brain metastases patients with non-small-cell lung 7-47 months, breast 3-36 months, melanoma 5-34 months, GI 3-17 months, and renal cancer 4-35 months. The survival ranges were updated on the assessment tool can be used to stratify patients with metastatic cancer of the brain to trial therapies that patients conventionally may not have been considered for due to their presumed prognosis with brain metastasis. This was a Retrospective cohort (described as a Multi-institutional database) with 6984 patients who were Patients with newly diagnosed metastatic cancer to the brain.
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto WA, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, An Y, Chiang V, Nakano T, Aoyama H, Mehta MP. Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol. 2020 Nov 10;38(32):3773-3784. doi: 10.1200/JCO.20.01255. Epub 2020 Sep 15. PMID: 32931399; PMCID: PMC7655019.
